Neurocrine Biosciences Inc (NBIX) is the 28th largest of 300 Pharmaceuticals companies by market capitalisation, at 15.58 Bn, behind Madrigal Pharmaceuticals, Inc. at 15.84 Bn. It trades on a P/E of 22.08, 16% above the peer median of 18.98. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JNJ | Johnson & Johnson | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 646.71 Bn | 30.74 | 6.60 | 625.95 Bn |
| 2 | ABBV | AbbVie Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 442.22 Bn | 70.02 | 6.87 | 435.65 Bn |
| 3 | MRK | Merck & Co., Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 366.92 Bn | 115.78 | 5.51 | 359.78 Bn |
| 4 | NVS | Novartis Ag | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 266.90 Bn | 9.27 | 3.88 | 259.21 Bn |
| 5 | PFE | Pfizer Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 159.20 Bn | 36.45 | 2.50 | 147.50 Bn |
| 6 | SNY | Sanofi | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 52.44 Bn | 11.25 | 0.98 | 45.06 Bn |
| 7 | RVMD | Revolution Medicines, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 44.11 Bn | -24.95 | — | 44.11 Bn |
| 8 | INCY | Incyte Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 25.38 Bn | 15.74 | 4.36 | 20.85 Bn |
| 9 | UTHR | UNITED THERAPEUTICS Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 21.50 Bn | 16.40 | 6.82 | 18.84 Bn |
| 10 | NBIX | Neurocrine Biosciences Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.58 Bn | 22.08 | 4.62 | 15.19 Bn |
| 11 | JAZZ | Jazz Pharmaceuticals plc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.11 Bn | 16.06 | 3.28 | 13.50 Bn |
| 12 | EXEL | Exelixis, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 14.52 Bn | 16.87 | 5.96 | 13.68 Bn |
| 13 | CORT | Corcept Therapeutics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 12.15 Bn | 224.07 | 14.62 | 11.84 Bn |
| 14 | KYMR | Kymera Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 11.32 Bn | -37.78 | 107.81 | 10.63 Bn |
| 15 | AXSM | Axsome Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 10.88 Bn | -70.78 | 14.01 | 10.56 Bn |
| 16 | CYTK | Cytokinetics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 9.78 Bn | -13.34 | 144.57 | 8.62 Bn |
| 17 | NUVL | Nuvalent, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 9.75 Bn | -27.07 | — | 9.75 Bn |
| 18 | GPCR | Structure Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 9.07 Bn | -48.22 | — | 9.07 Bn |
| 19 | CRNX | Crinetics Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 8.99 Bn | -17.90 | 213.22 | 8.99 Bn |
| 20 | ALKS | Alkermes plc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 7.57 Bn | 114.43 | 4.54 | 6.91 Bn |
| 21 | TVTX | Travere Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 6.19 Bn | -142.37 | 10.46 | 6.07 Bn |
| 22 | BLTE | Belite Bio, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 6.16 Bn | 0.08 | — | 6.16 Bn |
| 23 | LQDA | Liquidia Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 6.08 Bn | 43.84 | 13.47 | 5.79 Bn |
| 24 | AMRN | Amarin Corp Plc\Uk | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 5.96 Bn | -219.86 | 32.02 | 5.65 Bn |
| 25 | ACAD | Acadia Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.77 Bn | 12.54 | 4.19 | 3.81 Bn |
| 26 | EWTX | Edgewise Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.67 Bn | -23.70 | — | 4.67 Bn |
| 27 | DFTX | Definium Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.24 Bn | -11.99 | — | 4.24 Bn |
| 28 | INDV | Indivior Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.08 Bn | 11.50 | 3.06 | 3.86 Bn |
| 29 | MANE | Veradermics, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.03 Bn | -46.77 | — | 4.03 Bn |
| 30 | CPRX | CATALYST PHARMACEUTICALS, INC. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.85 Bn | 17.94 | 6.45 | 3.09 Bn |
| 31 | ELVN | Enliven Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.80 Bn | -45.18 | — | 3.80 Bn |
| 32 | TARS | Tarsus Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.63 Bn | -77.26 | 5.98 | 3.18 Bn |
| 33 | OGN | Organon & Co. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.59 Bn | 17.19 | 0.59 | 2.46 Bn |
| 34 | NAMS | NewAmsterdam Pharma Co N.V. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.87 Bn | -11.07 | 403.24 | 2.87 Bn |
| 35 | MLYS | Mineralys Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.64 Bn | -7.54 | — | 2.64 Bn |
| 36 | TAK | Takeda Pharmaceutical Co Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.62 Bn | 4.56 | 0.06 | -3.18 Bn |
| 37 | TRVI | Trevi Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.60 Bn | -61.63 | — | 2.60 Bn |
| 38 | BEIGF | BeOne Medicines Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.48 Bn | 3.74 | 0.40 | -2.62 Bn |
| 39 | SUPN | Supernus Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.43 Bn | -28.53 | 3.08 | 2.06 Bn |
| 40 | HRMY | Harmony Biosciences Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.41 Bn | 13.51 | 2.51 | 1.60 Bn |
| 41 | NUVB | Nuvation Bio Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.28 Bn | -21.06 | 13.40 | 2.28 Bn |
| 42 | PVLA | Palvella Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.19 Bn | -41.33 | — | 1.88 Bn |
| 43 | AUPH | Aurinia Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.11 Bn | 6.71 | 6.77 | 1.66 Bn |
| 44 | ETON | Eton Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.64 Bn | 171.75 | 16.36 | 1.61 Bn |
| 45 | INVA | Innoviva, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.55 Bn | 7.89 | 3.01 | 0.97 Bn |
| 46 | LBRX | Lb Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | -24.11 | — | 1.46 Bn |
| 47 | HROW | Harrow, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.41 Bn | -42.05 | 5.10 | 1.32 Bn |
| 48 | XERS | Xeris Biopharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | -80.40 | 4.11 | 1.26 Bn |
| 49 | OPK | Opko Health, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.18 Bn | -31.10 | 2.00 | 0.88 Bn |
| 50 | OLMA | Olema Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.10 Bn | -5.36 | — | 1.10 Bn |
| 51 | KURA | Kura Oncology, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.07 Bn | -4.49 | 13.85 | 1.07 Bn |
| 52 | PCRX | Pacira BioSciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.02 Bn | 69.39 | 1.36 | 0.76 Bn |
| 53 | DSGN | Design Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.95 Bn | -11.76 | — | 0.74 Bn |
| 54 | LXRX | Lexicon Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.94 Bn | -14.89 | 22.59 | 0.75 Bn |
| 55 | SGP | SpyGlass Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.93 Bn | -48.72 | — | 0.93 Bn |
| 56 | VSTM | Verastem, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.78 Bn | -6.79 | 8.94 | 0.65 Bn |
| 57 | COLL | Collegium Pharmaceutical, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.76 Bn | 15.89 | 0.94 | 0.61 Bn |
| 58 | PHAT | Phathom Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.73 Bn | -7.47 | 3.06 | 0.55 Bn |
| 59 | ZVRA | Zevra Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.72 Bn | 12.34 | 5.28 | 0.50 Bn |
| 60 | GYRE | Gyre Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.70 Bn | -38.09 | 5.89 | 0.65 Bn |
| 61 | IVEVF | Inventiva S.A. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.69 Bn | 7.19 | 132.94 | 0.69 Bn |
| 62 | CRMD | CorMedix Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | 5.06 | 1.70 | 0.38 Bn |
| 63 | AQST | Aquestive Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | -8.14 | 11.77 | 0.54 Bn |
| 64 | MPLT | MapLight Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.62 Bn | -3.07 | — | 0.62 Bn |
| 65 | EOLS | Evolus, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.57 Bn | -16.61 | 1.80 | 0.53 Bn |
| 66 | NVCT | Nuvectis Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.54 Bn | -17.93 | — | 0.54 Bn |
| 67 | OVID | Ovid Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.54 Bn | -15.54 | 338.65 | 0.42 Bn |
| 68 | SPRY | ARS Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.52 Bn | -2.37 | 4.48 | 0.38 Bn |
| 69 | XFOR | X4 Pharmaceuticals, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | -5.07 | 28.82 | 0.26 Bn |
| 70 | PALI | Palisade Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | -12.55 | 885.69 | 0.32 Bn |
| 71 | IKT | Inhibikase Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.42 Bn | -6.39 | — | 0.26 Bn |
| 72 | VTVT | vTv Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.42 Bn | -87.28 | 11.27 | 0.42 Bn |
| 73 | TTRX | Turn Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | -53.19 | — | 0.41 Bn |
| 74 | SION | Sionna Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | -3.47 | — | 0.34 Bn |
| 75 | ACHV | Achieve Life Sciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.33 Bn | — | — | 0.33 Bn |
| 76 | VNDA | Vanda Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -1.15 | 1.46 | 0.15 Bn |
| 77 | IMRX | Immuneering Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | -5.09 | — | 0.30 Bn |
| 78 | FULC | Fulcrum Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | -3.29 | — | 0.29 Bn |
| 79 | EBS | Emergent BioSolutions Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | -1.64 | 0.38 | 0.15 Bn |
| 80 | ZNTL | Zentalis Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | -1.95 | — | 0.27 Bn |
| 81 | AKBA | Akebia Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -8.76 | 1.19 | 0.10 Bn |
| 82 | CELG-RI | Bristol Myers Squibb Co | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | 0.02 | 0.00 | -10.84 Bn |
| 83 | SIGA | Siga Technologies Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | — | — | 0.07 Bn |
| 84 | TNXP | Tonix Pharmaceuticals Holding Corp. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -1.35 | 7.40 | 0.22 Bn |
| 85 | DERM | Journey Medical Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -56.25 | 3.02 | 0.18 Bn |
| 86 | ACOG | Alpha Cognition Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -7.29 | 14.95 | 0.16 Bn |
| 87 | CRDL | Cardiol Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -7.58 | — | 0.20 Bn |
| 88 | NERV | Minerva Neurosciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -29.87 | — | 0.20 Bn |
| 89 | SLGL | Sol-Gel Technologies Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -18.22 | 106.45 | 0.14 Bn |
| 90 | MCUJF | Medicure Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -37.45 | 8.18 | 0.19 Bn |
| 91 | LONA | LeonaBio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -1.44 | — | 0.12 Bn |
| 92 | MENS | Jyong Biotech Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -46.69 | — | 0.17 Bn |
| 93 | LENZ | LENZ Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -1.21 | 7.28 | 0.16 Bn |
| 94 | BMEA | Biomea Fusion, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -2.37 | — | 0.13 Bn |
| 95 | VANI | Vivani Medical, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -4.23 | — | 0.10 Bn |
| 96 | VRCA | Verrica Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -3.52 | 3.65 | 0.10 Bn |
| 97 | AARD | Aardvark Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -1.56 | — | 0.03 Bn |
| 98 | TENX | Tenax Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -1.49 | — | 0.10 Bn |
| 99 | CPIX | Cumberland Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -8.92 | 3.07 | 0.09 Bn |
| 100 | NTHI | Neonc Technologies Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -2.05 | — | 0.09 Bn |
| 101 | CGTX | Cognition Therapeutics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -2.46 | — | 0.09 Bn |
| 102 | MNOV | Medicinova Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -7.58 | 99.78 | 0.09 Bn |
| 103 | PTHS | Pelthos Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -0.76 | 1.57 | 0.06 Bn |
| 104 | RGC | Regencell Bioscience Holdings Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | — | — | 0.07 Bn |
| 105 | PMVP | PMV Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.19 | — | -0.01 Bn |
| 106 | PLRX | Pliant Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -0.77 | — | 0.07 Bn |
| 107 | BOLD | Boundless Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -1.00 | — | 0.06 Bn |
| 108 | VERU | Veru Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 117.37 | — | 0.03 Bn |
| 109 | GOSS | Gossamer Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.30 | 0.97 | -0.01 Bn |
| 110 | KPTI | Karyopharm Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.24 | 0.32 | -0.02 Bn |
| 111 | ANVS | Annovis Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.97 | — | 0.05 Bn |
| 112 | CLNN | Clene Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.33 | 212.70 | 0.04 Bn |
| 113 | APRE | Aprea Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -3.39 | — | 0.04 Bn |
| 114 | IXHL | Incannex Healthcare Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.85 | — | 0.04 Bn |
| 115 | GRCE | Grace Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.86 | — | 0.04 Bn |
| 116 | SCLX | Scilex Holding Co | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.08 | 1.17 | -0.08 Bn |
| 117 | CPHI | China Pharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -7.54 | 8.61 | 0.03 Bn |
| 118 | UG | United Guardian Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 14.47 | 2.92 | 0.02 Bn |
| 119 | ACTU | Actuate Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.52 | — | 0.03 Bn |
| 120 | NSRX | Nasus Pharma Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -5.64 | — | 0.03 Bn |
| 121 | CRVO | CervoMed Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.84 | 77.40 | 0.03 Bn |
| 122 | BYSI | BeyondSpring Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.95 | — | 0.02 Bn |
| 123 | YARW | Yarrow Bioscience, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.18 | 49.47 | 0.00 Bn |
| 124 | TXMD | TherapeuticsMD, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -133.26 | 7.54 | 0.02 Bn |
| 125 | AYTU | Aytu Biopharma, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.74 | 0.40 | 0.00 Bn |
| 126 | ATOS | Atossa Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.72 | — | 0.02 Bn |
| 127 | ALLR | Allarity Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.68 | 815.20 | 0.02 Bn |
| 128 | BFRI | Biofrontera Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -4.31 | 0.45 | 0.02 Bn |
| 129 | MIRA | Mira Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.57 | — | 0.01 Bn |
| 130 | TVRD | Tvardi Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.68 | — | 0.02 Bn |
| 131 | KPRX | Kiora Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.42 | — | 0.02 Bn |
| 132 | CTXR | Citius Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.33 | 2.17 | 0.02 Bn |
| 133 | ANEB | Anebulo Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -1.64 | — | 0.01 Bn |
| 134 | INTI | Inhibitor Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -3.67 | — | 0.01 Bn |
| 135 | CALC | CalciMedica, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.34 | -8.47 | -0.01 Bn |
| 136 | RVPH | Reviva Pharmaceuticals Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.74 | — | 0.01 Bn |
| 137 | ADXN | Addex Therapeutics Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | 0.05 | — | 0.01 Bn |
| 138 | ACXP | Acurx Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.81 | — | 0.01 Bn |
| 139 | CURX | Curanex Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.80 | — | 0.00 Bn |
| 140 | TRAW | Traws Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.35 | — | 0.00 Bn |
| 141 | PULM | Pulmatrix, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -1.37 | — | 0.01 Bn |
| 142 | PCSA | Processa Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.41 | — | 0.01 Bn |
| 143 | TCRT | Alaunos Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.93 | 1,261.64 | 0.00 Bn |
| 144 | BICX | BioCorRx Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -1.64 | 6.70 | 0.00 Bn |
| 145 | CVKD | Cadrenal Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.30 | — | 0.00 Bn |
| 146 | CASIF | CASI Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.02 | 0.12 | 0.00 Bn |
| 147 | OGEN | Oragenics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.23 | — | 0.00 Bn |
| 148 | CANF | Can-Fite BioPharma Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.24 | 5.93 | 0.00 Bn |
| 149 | UPC | Universe Pharmaceuticals INC | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | -1,490.23 Bn |
| 150 | ENSC | Ensysce Biosciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | 0.00 Bn |
| 151 | MTNB | Matinas BioPharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.16 | — | 0.00 Bn |
| 152 | SKVI | Skinvisible, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -1.05 | 54.04 | 0.00 Bn |
| 153 | SPRC | SciSparc Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.05 | 0.76 | 0.00 Bn |
| 154 | NCEL | NewcelX Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.06 | — | 0.00 Bn |
| 155 | GLMD | Galmed Pharmaceuticals Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | 0.00 Bn |
| 156 | CDT | CDT Equity Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.01 | — | 0.00 Bn |
| 157 | JAGX | Jaguar Health, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.01 | 0.01 | -0.01 Bn |
| 158 | GCAN | Trafalgar International, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -1.77 | — | 0.00 Bn |
| 159 | CINGW | Cingulate Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | — | 0.00 Bn |
| 160 | SXTC | China SXT Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | 0.03 | -0.03 Bn |
| 161 | CMND | Clearmind Medicine Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | — | -0.01 Bn |
| 162 | AMGN | Amgen Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 211.73 Bn | 24.22 | 5.56 | 197.75 Bn |
| 163 | GILD | Gilead Sciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 181.27 Bn | -62.62 | 5.95 | 178.09 Bn |
| 164 | VRTX | Vertex Pharmaceuticals Inc / Ma | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 132.28 Bn | 30.03 | 10.51 | 124.42 Bn |
| 165 | REGN | Regeneron Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 82.76 Bn | 19.12 | 5.33 | 74.77 Bn |
| 166 | ARGX | Argenx Se | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 61.59 Bn | 35.91 | 11.79 | 56.41 Bn |
| 167 | MRNA | Moderna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 54.65 Bn | -17.34 | 24.53 | 49.52 Bn |
| 168 | TEVA | Teva Pharmaceutical Industries Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 42.61 Bn | 61.22 | 2.46 | 38.95 Bn |
| 169 | ALC | Alcon Inc | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 34.03 Bn | 52.92 | 3.16 | 32.57 Bn |
| 170 | ALNY | Alnylam Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 33.96 Bn | 43.84 | 7.07 | 30.66 Bn |
| 171 | BIIB | Biogen Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 31.22 Bn | 37.41 | 3.11 | 29.93 Bn |
| 172 | ROIV | Roivant Sciences Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 29.94 Bn | -20.17 | 2,741.06 | 29.94 Bn |
| 173 | GEHC | GE HealthCare Technologies Inc. | secondary | H-08 | Medical Devices and Diagnostics | HG-02 | 29.61 Bn | 14.44 | 1.39 | 27.50 Bn |
| 174 | INSM | INSMED Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 28.15 Bn | -32.16 | 24.75 | 26.99 Bn |
| 175 | BNTX | BioNTech SE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 23.67 Bn | -13.89 | 7.65 | 10.02 Bn |
| 176 | VTRS | Viatris Inc | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 19.18 Bn | -46.71 | 1.30 | 18.30 Bn |
| 177 | ZBH | Zimmer Biomet Holdings, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 18.27 Bn | 21.56 | 2.15 | 17.86 Bn |
| 178 | ASND | Ascendis Pharma A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.89 Bn | 18.33 | 11.21 | 14.95 Bn |
| 179 | MDGL | Madrigal Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.84 Bn | -49.64 | 12.33 | 15.00 Bn |
| 180 | BBIO | BridgeBio Pharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.91 Bn | -21.55 | 20.91 | 14.19 Bn |
| 181 | BWXT | BWX Technologies, Inc. | secondary | I-39 | Clean Energy Equipment | IG-10 | 14.44 Bn | 40.54 | 4.11 | 13.83 Bn |
| 182 | SMMT | Summit Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.66 Bn | — | — | 12.97 Bn |
| 183 | HALO | Halozyme Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.59 Bn | 30.44 | 7.57 | 12.36 Bn |
| 184 | BMRN | Biomarin Pharmaceutical Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.58 Bn | 172.35 | 3.69 | 11.70 Bn |
| 185 | ARWR | Arrowhead Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 11.95 Bn | -43.90 | 17.84 | 10.34 Bn |
| 186 | AAVXF | Abivax S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.92 Bn | -25.97 | — | 10.92 Bn |
| 187 | GKOS | GLAUKOS Corp | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 10.60 Bn | -67.29 | 17.29 | 10.48 Bn |
| 188 | APGE | Apogee Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | -34.62 | — | 9.20 Bn |
| 189 | PRAX | Praxis Precision Medicines, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.14 Bn | -26.59 | — | 9.38 Bn |
| 190 | KRYS | Krystal Biotech, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 10.12 Bn | 41.89 | 22.96 | 9.27 Bn |
| 191 | GMED | Globus Medical Inc | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 10.09 Bn | 18.84 | 3.21 | 9.49 Bn |
| 192 | RDY | Dr Reddys Laboratories Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 9.85 Bn | 780.84 | 2.69 | 9.68 Bn |
| 193 | PTGX | Protagonist Therapeutics, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.54 Bn | 86.43 | 33.84 | 9.54 Bn |
| 194 | IONS | Ionis Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.33 Bn | -43.94 | 10.67 | 7.27 Bn |
| 195 | PCVX | Vaxcyte, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.55 Bn | -8.09 | — | 8.55 Bn |
| 196 | IBRX | ImmunityBio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.42 Bn | -8.48 | 50.77 | 8.06 Bn |
| 197 | IMVT | Immunovant, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.97 Bn | -14.80 | — | 7.97 Bn |
| 198 | TGTX | Tg Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.73 Bn | 17.50 | 9.67 | 7.05 Bn |
| 199 | GIFLF | Grifols SA | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.54 Bn | 29.70 | 0.46 | 9.09 Bn |
| 200 | SYRE | Spyre Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.48 Bn | -41.79 | — | 7.48 Bn |
| 201 | SRRK | Scholar Rock Holding Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.13 Bn | -17.66 | — | 7.13 Bn |
| 202 | RYTM | Rhythm Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.93 Bn | -32.95 | 28.87 | 6.60 Bn |
| 203 | BLCO | Bausch & Lomb Corp | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 6.45 Bn | -39.57 | 1.21 | 6.07 Bn |
| 204 | BLRX | BioLineRx Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.34 Bn | -707.43 | 4,551.55 | 6.34 Bn |
| 205 | CGON | CG Oncology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.31 Bn | -28.14 | 1,012.57 | 6.31 Bn |
| 206 | MIRM | Mirum Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.31 Bn | -7.33 | 10.20 | 5.87 Bn |
| 207 | KNSA | Kiniksa Pharmaceuticals International, plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.14 Bn | 76.13 | 7.30 | 5.61 Bn |
| 208 | COGT | Cogent Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.92 Bn | -16.01 | — | 5.92 Bn |
| 209 | DBVT | DBV Technologies S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.86 Bn | -33.28 | 1,166.98 | 5.68 Bn |
| 210 | XENE | Xenon Pharmaceuticals Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.86 Bn | -16.15 | — | 5.86 Bn |
| 211 | LGND | Ligand Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.82 Bn | 29.52 | 20.04 | 4.47 Bn |
| 212 | ORKA | Oruka Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.77 Bn | — | — | 4.04 Bn |
| 213 | PTCT | Ptc Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.61 Bn | 14.68 | 5.57 | 3.39 Bn |
| 214 | AMRX | Amneal Pharmaceuticals, Inc. | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 5.48 Bn | 25.45 | 1.76 | 5.35 Bn |
| 215 | CRSP | CRISPR Therapeutics AG | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 5.23 Bn | -10.81 | 390.47 | 5.23 Bn |
| 216 | ERAS | Erasca, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.00 Bn | -17.40 | — | 5.00 Bn |
| 217 | CELC | Celcuity Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.97 Bn | -22.69 | — | 4.97 Bn |
| 218 | FMCQF | Fresenius Medical Care AG | secondary | H-14 | Healthcare Providers | HG-04 | 4.79 Bn | 4.57 | 0.17 | 4.09 Bn |
| 219 | DNLI | Denali Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.09 Bn | -8.00 | 1,135.11 | 4.09 Bn |
| 220 | DNTH | Dianthus Therapeutics, Inc. /DE/ | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.03 Bn | — | — | 3.62 Bn |
| 221 | TLPPF | Telix Pharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.89 Bn | -521.64 | 4.64 | 3.59 Bn |
| 222 | IOVA | Iovance Biotherapeutics, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 3.86 Bn | -18.47 | 11.88 | 3.56 Bn |
| 223 | RLAY | Relay Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.85 Bn | -13.46 | 371.89 | 3.85 Bn |
| 224 | VKTX | Viking Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.80 Bn | -7.11 | — | 3.80 Bn |
| 225 | LEGN | Legend Biotech Corp | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 3.67 Bn | -174.32 | 2.89 | 2.71 Bn |
| 226 | AMLX | Amylyx Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.66 Bn | -30.11 | — | 3.66 Bn |
| 227 | RCUS | Arcus Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.58 Bn | -7.79 | 30.63 | 2.88 Bn |
| 228 | TNGX | Tango Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.56 Bn | -34.74 | 66.07 | 2.54 Bn |
| 229 | IDYA | IDEAYA Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.55 Bn | -16.13 | 15.16 | 2.72 Bn |
| 230 | ABCL | AbCellera Biologics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.41 Bn | -20.74 | 51.60 | 3.41 Bn |
| 231 | DYN | Dyne Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.21 Bn | -6.21 | — | 3.21 Bn |
| 232 | ARQT | Arcutis Biotherapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.12 Bn | 109.68 | 6.73 | 2.89 Bn |
| 233 | QURE | uniQure N.V. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 3.08 Bn | -15.65 | 164.81 | 3.08 Bn |
| 234 | CLDX | Celldex Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.03 Bn | -9.85 | 19,154.55 | 3.03 Bn |
| 235 | IMNM | Immunome Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.98 Bn | -11.02 | 593.06 | 2.46 Bn |
| 236 | IRON | Disc Medicine, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.95 Bn | -14.66 | — | 2.95 Bn |
| 237 | MBX | MBX Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.92 Bn | -28.03 | — | 2.92 Bn |
| 238 | NRIX | Nurix Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.91 Bn | -8.53 | 79.19 | 2.47 Bn |
| 239 | ZLAB | Zai Lab Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.83 Bn | -15.01 | 6.29 | 2.12 Bn |
| 240 | CURLF | Curaleaf Holdings, Inc. | secondary | S-09 | Tobacco and Cannabis | SG-04 | 2.68 Bn | -22.60 | 2.05 | 2.58 Bn |
| 241 | BEAM | Beam Therapeutics Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.67 Bn | -31.28 | 17.12 | 2.67 Bn |
| 242 | SLS | SELLAS Life Sciences Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.65 Bn | -81.77 | — | 2.65 Bn |
| 243 | OCUL | Ocular Therapeutix, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.56 Bn | -8.46 | 49.20 | 2.56 Bn |
| 244 | AXGN | Axogen, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 2.56 Bn | -172.82 | 10.18 | 2.45 Bn |
| 245 | VERA | Vera Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.46 Bn | -6.15 | — | 2.46 Bn |
| 246 | PGEN | Precigen, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.43 Bn | -7.20 | 28.29 | 2.43 Bn |
| 247 | NKTR | Nektar Therapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.41 Bn | -20.30 | 44.18 | 1.73 Bn |
| 248 | VRDN | Viridian Therapeutics, Inc.\DE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.41 Bn | -6.03 | 33.89 | 2.41 Bn |
| 249 | BHC | Bausch Health Companies Inc. | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 2.36 Bn | -2.16 | 0.22 | 0.52 Bn |
| 250 | SRPT | Sarepta Therapeutics, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.33 Bn | -17.02 | 1.18 | 1.54 Bn |
| 251 | BCRX | Biocryst Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.31 Bn | -6.02 | 4.33 | 1.96 Bn |
| 252 | XTLB | Xtl Biopharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.29 Bn | -2,975.41 | — | 2.29 Bn |
| 253 | BHVN | Biohaven Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.29 Bn | -3.90 | — | 2.02 Bn |
| 254 | URGN | UroGen Pharma Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.27 Bn | -36.46 | 12.03 | 2.16 Bn |
| 255 | PHVS | Pharvaris N.V. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.25 Bn | -11.33 | — | 1.88 Bn |
| 256 | GMAB | Genmab A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.15 Bn | 0.17 | 0.34 | 0.65 Bn |
| 257 | KOD | Kodiak Sciences Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.14 Bn | -8.83 | — | 2.14 Bn |
| 258 | ADMA | Adma Biologics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.13 Bn | 12.83 | 4.17 | 2.00 Bn |
| 259 | RAPP | Rapport Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.09 Bn | -15.20 | 104.25 | 2.09 Bn |
| 260 | AGIO | Agios Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.08 Bn | -5.06 | 21.18 | 2.08 Bn |
| 261 | CMPS | COMPASS Pathways plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.07 Bn | -5.25 | — | 2.07 Bn |
| 262 | ZBIO | Zenas BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.03 Bn | -4.89 | 2,033.48 | 2.03 Bn |
| 263 | ZYME | Zymeworks Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.00 Bn | -13.32 | 53.81 | 1.73 Bn |
| 264 | VCEL | Vericel Corp | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.99 Bn | 79.43 | 6.51 | 1.83 Bn |
| 265 | TSHA | Taysha Gene Therapies, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.97 Bn | -13.18 | 359.62 | 1.97 Bn |
| 266 | STOK | Stoke Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.96 Bn | -9.43 | 71.00 | 1.67 Bn |
| 267 | XNCR | Xencor Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.90 Bn | -11.62 | 18.08 | 1.52 Bn |
| 268 | INBX | Inhibrx Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.82 Bn | -13.67 | 1,402.38 | 1.82 Bn |
| 269 | VIR | Vir Biotechnology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.81 Bn | -7.18 | 5.96 | 1.81 Bn |
| 270 | IMCR | Immunocore Holdings plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.78 Bn | -98.29 | 4.13 | 0.90 Bn |
| 271 | SNDX | Syndax Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.76 Bn | -9.70 | 6.97 | 1.21 Bn |
| 272 | SEPN | Septerna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.74 Bn | -124.58 | 17.59 | 1.74 Bn |
| 273 | RXRX | Recursion Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | -3.34 | 31.55 | 1.18 Bn |
| 274 | GLPGF | Lakefront Biotherapeutics NV | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | 0.00 | 1.50 | 1.73 Bn |
| 275 | GHRS | GH Research PLC | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.68 Bn | -26.97 | — | 1.32 Bn |
| 276 | NTLA | Intellia Therapeutics, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.66 Bn | -4.15 | 27.86 | 1.66 Bn |
| 277 | DMRA | Damora Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.64 Bn | -6.22 | — | 1.10 Bn |
| 278 | NVAX | Novavax Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.62 Bn | -6.55 | 3.92 | 0.90 Bn |
| 279 | SCNI | Scinai Immunotherapeutics Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.62 Bn | -192.89 | 938.23 | 1.61 Bn |
| 280 | BCAX | Bicara Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.60 Bn | -8.62 | — | 1.60 Bn |
| 281 | ATAI | AtaiBeckley Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.59 Bn | -10.36 | 525.18 | 1.59 Bn |
| 282 | ANAB | Anaptysbio, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.59 Bn | -66.54 | 7.98 | 1.30 Bn |
| 283 | FBRX | Forte Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | -20.71 | — | 1.23 Bn |
| 284 | AAPG | Ascentage Pharma Group International | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.54 Bn | -9.11 | 20.12 | 1.26 Bn |
| 285 | RARE | Ultragenyx Pharmaceutical Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.50 Bn | -3.24 | 2.09 | 1.21 Bn |
| 286 | ANIP | Ani Pharmaceuticals Inc | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 1.49 Bn | 13.78 | 1.52 | 1.13 Bn |
| 287 | ANRO | Alto Neuroscience, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.47 Bn | -17.49 | — | 1.47 Bn |
| 288 | GLUE | Monte Rosa Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | -9.49 | 50.87 | 0.83 Bn |
| 289 | MAZE | Maze Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.44 Bn | -13.62 | 72.21 | 1.44 Bn |
| 290 | SDGR | Schrodinger, Inc. | secondary | T-27 | Vertical Software | TG-05 | 1.44 Bn | -26.55 | 5.57 | 1.03 Bn |
| 291 | TYRA | Tyra Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.44 Bn | -9.67 | — | 1.44 Bn |
| 292 | AVBP | ArriVent BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.41 Bn | -8.62 | — | 1.41 Bn |
| 293 | REPL | Replimune Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.41 Bn | -4.74 | — | 1.41 Bn |
| 294 | SLDB | Solid Biosciences Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.40 Bn | -6.88 | — | 1.40 Bn |
| 295 | OMER | Omeros Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.39 Bn | 81.67 | 36.28 | 1.39 Bn |
| 296 | ABSI | Absci Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.39 Bn | -11.48 | 890.25 | 1.19 Bn |
| 297 | SVRA | Savara Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | -9.84 | — | 1.37 Bn |
| 298 | ORIC | Oric Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.36 Bn | -8.66 | — | 1.36 Bn |
| 299 | CGEM | Cullinan Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.32 Bn | -6.46 | — | 1.32 Bn |
| 300 | VOR | Vor Biopharma Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.28 Bn | -1.39 | — | 1.28 Bn |